Voruciclib is a small molecule inhibitor primarily targeting cyclin-dependent kinases (CDKs), particularly CDK9, which plays a crucial role in regulating transcription and cell cycle progression. This compound is part of a class of drugs designed to interfere with the activity of CDKs, thereby inhibiting cancer cell proliferation. Voruciclib has shown potential in preclinical studies for treating various types of cancers, including hematological malignancies and solid tumors. Its mechanism of action involves disrupting the phosphorylation of RNA polymerase II, leading to the downregulation of oncogenic transcription factors. Voruciclib is characterized by its specific binding affinity to CDK9, which contributes to its efficacy in cancer therapy. Additionally, it is important to consider its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which influence its therapeutic potential and safety profile. Ongoing clinical trials are assessing its effectiveness and safety in combination with other therapies, aiming to enhance treatment outcomes for patients with resistant or advanced cancers.

Voruciclib

1000023-04-0: Voruciclib is a small molecule inhibitor primarily targeting cyclin-dependent kinases (CDKs), particularly CDK9, which plays a crucial role in regulating transcription and cell cycle progression. This compound is part of a class of drugs designed to interfere with the activity of CDKs, thereby inhibiting cancer cell proliferation. Voruciclib has shown potential in preclinical studies for treating various types of cancers, including hematological malignancies and solid tumors. Its mechanism of action involves disrupting the phosphorylation of RNA polymerase II, leading to the downregulation of oncogenic transcription factors. Voruciclib is characterized by its specific binding affinity to CDK9, which contributes to its efficacy in cancer therapy. Additionally, it is important to consider its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which influence its therapeutic potential and safety profile. Ongoing clinical trials are assessing its effectiveness and safety in combination with other therapies, aiming to enhance treatment outcomes for patients with resistant or advanced cancers.

2-[2-Chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one

<p>Voruciclib: oral, selective CDK inhibitor (Ki: 0.626-9.1 nM), reduces MCL-1, targets CDK9 in diffuse large B-cell lymphoma.</p>

CAS 1000023-04-0

Voruciclib

2-[2-Chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one

Ref: IN-DA0092WG

Voruciclib

Ref: 54-BUP00389

Voruciclib

Ref: TM-T10096L

VORUCICLIB

Ref: 10-F811928